Drug intelligence / Profile preview

QSHY granule

Development stage: Unknown
Lead developer: Shuguang Hospital
Administration: Oral

Overview

QSHY granule is a Traditional Chinese Medicine (TCM) formulation developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine for the treatment of hyperlipidemia. The name "QSHY" is an abbreviation for "Qu-Shi-Hua-Yu" (祛湿化瘀), which refers to the TCM therapeutic principle of removing dampness and resolving blood stasis. These pathological patterns are considered central to the development of lipid metabolism disorders in TCM theory. The formulation is typically composed of multiple herbal extracts and is administered orally as a granule to regulate lipid profiles, including the reduction of total cholesterol and triglycerides, in patients diagnosed with the phlegm and blood stasis type of hyperlipidemia.

Other names: Qu-Shi-Hua-Yu granuleQSHY formula

Beyond the preview

Go deeper on QSHY granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QSHY granule.

Explore the full profile